The DOI matches its Crossref record.
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.
Abstract
Adoptive immunotherapy with lymphokine-activated killer cells and recombinant interleukin 2 (IL 2) can produce significant reduction of visceral metastases in tumor-bearing mice and, as shown recently, in humans with disseminated cancer. Because further dose escalations of IL 2 have been prevented by the development of a vascular leak syndrome (VLS) in both mice and humans, we investigated this VLS in mice undergoing the systemic administration of high-dose IL 2. A model for quantitating capillary permeability was used in which 125I-bovine serum albumin was injected i.v., and 2 hr later, tissues were counted in a gamma analyzer. A permeability index (PI) was calculated by dividing the mean counts per minute (cpm) of tissues from IL 2-treated mice by those from control animals. The injection of IL 2 produced increases in vascular permeability that were most pronounced in the thymus, spleen, lungs, liver, and kidneys (PI = 18.0, 10.0, 9.7, 6.7, and 6.3, respectively, on day 6). The development of the VLS was highly dependent on the number of days of IL 2 treatment (for example, the lungs contained 638, 1382, 3350, and 6187 cpm after 0, 1, 3, and 6 days of IL 2, respectively). Moreover, the degree of the VLS was directly related to the dose of IL 2 administered. Measurement of the wet and dry weights of lungs from IL 2-treated mice demonstrated that IL 2 produced a dramatic increase in their water weight (from 0.10 g at base line to 0.22 g after 200,000 U of IL 2 for 6 days). The injection of the IL 2 excipient failed to induce capillary leakage in tissues. Immunosuppression of mice by pretreatment irradiation (500 rad) or by injection of cyclophosphamide or by concurrent use of cortisone acetate markedly reduced or eliminated the development of the VLS. Similarly, the VLS was not observed in nude mice receiving IL 2. Thus, the administration of IL 2 produces a dose-limiting VLS that may be mediated, directly or indirectly, by host lymphoid elements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Self-citationRosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389
Self-citationTumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.
Connolly, D. T., Heuvelman, D. M., Nelson, R., Olander, J. V., Eppley, B. L., Delfino, J. J., Siegel, N. R., Leimgruber, R. M., & Feder, J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114322 · Cited by 1,265
Rosenberg, S. A. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510360033032 · Cited by 1,131
Self-citationExperience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
ROSENBERG, S. A., LOTZE, M. T., YANG, J. C., AEBERSOLD, P. M., LINEHAN, W. M., SEIPP, C. A., & WHITE, D. E. (1989) · Annals of Surgery · doi:10.1097/00000658-198910000-00008 · Cited by 1,002
Self-citationA Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice
Huh, D., Leslie, D. C., Matthews, B. D., Fraser, J. P., Jurek, S., Hamilton, G. A., Thorneloe, K. S., McAlexander, M. A., & Ingber, D. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004249 · Cited by 993
Modeling immunotherapy of the tumor - immune interaction
Kirschner, D., & Panetta, J. C. (1998) · Journal of Mathematical Biology · doi:10.1007/s002850050127 · Cited by 915
Brandt, S. J., Peters, W. P., Atwater, S. K., Kurtzberg, J., Borowitz, M. J., Jones, R. B., Shpall, E. J., Bast, R. C., Gilbert, C. J., & Oette, D. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181401 · Cited by 754
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Siegel, J. P., & Puri, R. K. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.694 · Cited by 465
The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells
DENICOFF, K. D., RUBINOW, D. R., PAPA, M. Z., SIMPSON, C., SEIPP, C. A., LOTZE, M. T., CHANG, A. E., ROSENSTEIN, D., & ROSENBERG, S. A. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-293 · Cited by 455
Self-citationKarnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.
Rosenberg, S. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.180 · Cited by 390
Self-citationKrieg, C., Létourneau, S., Pantaleo, G., & Boyman, O. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002569107 · Cited by 380
Capillary leak syndrome: etiologies, pathophysiology, and management
Siddall, E., Khatri, M., & Radhakrishnan, J. (2017) · Kidney International · doi:10.1016/j.kint.2016.11.029 · Cited by 364
Clinical and Radiologic Features of Pulmonary Edema
Gluecker, T., Capasso, P., Schnyder, P., Gudinchet, F., Schaller, M.-D., Revelly, J.-P., Chiolero, R., Vock, P., & Wicky, S. (1999) · RadioGraphics · doi:10.1148/radiographics.19.6.g99no211507 · Cited by 330
Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders
Müller, N., & Ackenheil, M. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(97)00179-6 · Cited by 306
Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignancies
ATZPODIEN, J. (1990) · The Lancet · doi:10.1016/0140-6736(90)93039-r · Cited by 292
Vascular leak syndrome: a side effect of immunotherapy
Baluna, R., & Vitetta, E. S. (1997) · Immunopharmacology · doi:10.1016/s0162-3109(97)00041-6 · Cited by 280
Intratumoral LAK cell and interleukin-2 therapy of human gliomas
Barba, D., Saris, S. C., Holder, C., Rosenberg, S. A., & Oldfield, E. H. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.70.2.0175 · Cited by 252
Self-citationPenetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier
Saris, S. C., Rosenberg, S. A., Friedman, R. B., Rubin, J. T., Barba, D., & Oldfield, E. H. (1988) · Journal of Neurosurgery · doi:10.3171/jns.1988.69.1.0029 · Cited by 79
Self-citation
Metadata
- Authors
- Rosenstein, M., Ettinghausen, S. E., & Rosenberg, S. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1986-09-01
- Volume
- 137
- Issue
- 5
- Pages
- 1735-1742
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1529386421
- Cited by
- 530
- References
- 0
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.